Menu
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Context
A medical device company, active in the field of cardiovascular diseases wanted to apply for national reimbursement in Belgium.
Objective
The company asked Vivactis-HM3A to prepare and file the national reimbursement dossier in Belgium.
The reimbursement landscape in Belgium is challenging. Hence, Belgium served as a pilot before proceeding with the submission in other EU countries.
Assessment phase
Our consultants collected relevant scientific and clinical information from the client and the public space: CE marking, the results of the conducted studies, declaration of conformity, …
After evaluation of the complete data set and gauging the therapeutic and economic value of the proposed technology, we presented the action plan to the client and the class under which this device could be submitted.
Execution Phase
Our market access specialist extracted all relevant information in order to complete the template from RIZIV/INAMI. In parallel, our health economist built a Budget Impact Model (BIM) and ran a Budget Impact Analysis (BIA). In addition, a mapping was done of the reimbursement status in other EU member states.
Our consultant fostered close collaboration and short communication lines with the client, which has been a key element in the process.
Results
In a couple of months the reimbursement dossier has been finalized and submitted to RIZIV/INAMI.
RIZIV/INAMI had no questions and reimbursement has been approved.
The client is planning to apply for reimbursement in other EU countries in collaboration with Vivactis-HM3A. In addition, a Global Value Dossier is being prepared based on the Belgian dossier.